First Quadrant’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

First Quadrant’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,166	Closed	-$35K	–	715
2019 Q2	$35K	Sell	1,166 -195	-14%	-$4.47K	﹤0.01%	655
2019 Q1	$30K	Hold	1,361	–	–	﹤0.01%	666
2018 Q4	$25K	Hold	1,361	–	–	﹤0.01%	759
2018 Q3	$25K	Buy	+1,361	New	+$16.1K	﹤0.01%	798

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

First Quadrant's RARX Position: Q3 2019 in Review

First Quadrant sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q3 2019, closing a stake of 1,166 shares — an estimated $35K sold.

First Quadrant first reported a position in RARX in Q3 2018 and held it in 4 quarters. The position peaked at $35K in Q2 2019. 119 funds tracked by Wall St. Rank hold RARX as of Q3 2019.

First Quadrant reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
First Quadrant sold 1,166 Ra Pharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $35K.
First Quadrant first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 4 quarters.
First Quadrant's Ra Pharmaceuticals, Inc. Common Stock position peaked at $35K in Q2 2019.
119 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on First Quadrant's 13F filing for Q3 2019, filed 25 Oct 2019.